{"id":502009,"date":"2026-06-20T04:52:16","date_gmt":"2026-06-20T04:52:16","guid":{"rendered":"https:\/\/www.newsbeep.com\/il\/502009\/"},"modified":"2026-06-20T04:52:16","modified_gmt":"2026-06-20T04:52:16","slug":"certara-cert-stock-sees-fair-value-edges-lower-as-analysts-trim-targets","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/il\/502009\/","title":{"rendered":"Certara (CERT) Stock Sees Fair Value Edges Lower As Analysts Trim Targets"},"content":{"rendered":"\n

Make better investment decisions<\/a> with Simply Wall St’s easy, visual tools that give you a competitive edge.<\/p>\n

Certara\u2019s updated analyst model now carries a slightly lower fair value price target of US$7.48, compared with the prior US$7.62, reflecting only a modest adjustment. This small move aligns with recent Street commentary, where bullish analysts highlight profitable operations and long term growth drivers, while more cautious voices trim targets as they reassess valuation multiples and execution timelines. As you read on, you will see how these shifting views fit together and how to keep track of the evolving Certara narrative.<\/p>\n

Analyst Price Targets don’t always capture the full story. Head over to our Company Report to find new ways to value Certara.<\/a><\/p>\n

What Wall Street Has Been Saying \ud83d\udc02 Bullish Takeaways <\/p>\n

Leerink argues that Certara is highly profitable with multiple long term growth drivers, and views current trading levels as overly depressed relative to these fundamentals.<\/p>\n

Using the recent acquisition of peer Simulations Plus as a reference point, Leerink highlights that the implied takeout premium is roughly 90% above its own 2027 EV\/EBITDA valuation for Certara. The firm sees this as supportive of a higher potential trading multiple for the stock.<\/p>\n

Leerink also points to Certara\u2019s push into model informed drug discovery and the current investment period under new leadership as key factors that could support steadier revenue trends alongside EBITDA margins above 30%.<\/p>\n

\ud83d\udc3b Bearish Takeaways <\/p>\n

Several firms, including Craig Hallum, BMO Capital, Stephens, Baird, Morgan Stanley, Barclays, and KeyBanc, have all cut their Certara price targets, signaling concern about valuation levels and execution timelines even as they continue to cover the stock.<\/p>\n

These target reductions suggest that, while Certara\u2019s profitability and growth avenues are acknowledged, some analysts are recalibrating expectations for how quickly the company can translate its current initiatives into results that justify prior valuation multiples.<\/p>\n

Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there’s more to the story. Head to the Simply Wall St Community to discover more perspectives!<\/a><\/p>\n

\"NasdaqGS:CERT<\/a> NasdaqGS:CERT 1-Year Stock Price Chart <\/p>\n

See how Certara’s fair value stacks up across multiple valuation models \u2014 not just analyst targets.<\/a><\/p>\n

How This Changes the Fair Value For Certara <\/p>\n

Fair value revised slightly lower to US$7.48 from US$7.62, an adjustment of about 1.8%.<\/p>\n

Revenue growth held effectively steady at about 133.60%, with only a minimal numerical update in the model.<\/p>\n

Net profit margin maintained at roughly 187.48%, with a very small technical adjustment to the input figure.<\/p>\n

Future P\/E reduced modestly to about 165.75x from 168.89x in the updated Certara stock model.<\/p>\n

Discount rate adjusted marginally to 8.77% from 8.79% for assessing future cash flows.<\/p>\n

Story Continues <\/p>\n

Never Miss an Update: Follow The Narrative <\/p>\n

Narratives connect Certara\u2019s business story to the underlying forecasts and fair value assumptions that analysts are using. They update as new data, guidance, and news flow through, so you can see how the thesis is evolving in real time.<\/p>\n

Head over to the Simply Wall St Community and follow the Narrative on Certara<\/a> to stay up to date on:<\/p>\n

How regulatory momentum, including EMA qualification of Simcyp and the FDA\u2019s guidance on reduced animal testing, is supporting demand for Certara\u2019s biosimulation and model informed drug development platforms.<\/p>\n

The role of product development, cloud based SaaS delivery, and acquisitions such as Applied BioMath and Formedix in supporting recurring revenue, cross selling, and margin structure.<\/p>\n

Key risks around pharma customers adopting new technologies, concentration among large clients, and the possibility that rising R&D and integration costs may not generate the expected returns.<\/p>\n

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.<\/p>\n

Companies discussed in this article include CERT<\/a>.<\/p>\n

Have feedback on this article? Concerned about the content? Get in touch<\/a> with us directly. Alternatively, email editorial-team@simplywallst.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Make better investment decisions with Simply Wall St’s easy, visual tools that give you a competitive edge. Certara\u2019s…\n","protected":false},"author":2,"featured_media":453384,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[114,230799,11628,85,28655,46,230800],"class_list":["post-502009","post","type-post","status-publish","format-standard","has-post-thumbnail","category-business","tag-business","tag-certara","tag-fair-value","tag-il","tag-investment-decisions","tag-israel","tag-profitable-operations"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/502009","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/comments?post=502009"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/502009\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media\/453384"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media?parent=502009"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/categories?post=502009"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/tags?post=502009"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}